Skip to main content

Table 2 Effect of lycopene (1-5 μM) on cell cycle progression in different human cancer cell lines after 96 hours

From: Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines

Cell Lines

Cell Cycle phase

CT

1 μM

3 μM

5 μM

HT-29

G0/G1

77.14 ± 0.02

84.37 ±0.10*

40.29 ± 5.40**

46.07 ± 0.68**

S

8.31 ± 0.45

4.40 ± 1.06

19.59 ± 4.02*

9.30 ± 0.47

G2/M

13.41 ± 0.70

10.17 ± 0.32*

34.72 ± 0.86**

40.03 ± 0.38**

T84

G0/G1

28.14 ± 0.01

41.84 ± 1.53**

32.97 ± 0.28**

36.06 ± 0.06**

S

17.86 ± 1.03

17.52 ± 0.05

18.85 ± 0.20

19.39 ± 3.93

G2/M

43.67 ± 0.01

38.51 ± 1.48*

45.64 ± 0.51

50.23 ± 0.01*

MCF-7

G0/G1

17.10 ± 1.56

22.45 ± 0.78*

19.30 ± 0.99*

20.20 ± 1.13*

S

26.25 ± 0.35

26.95 ± 0.07

24.15 ± 1.20

22.95 ± 1.48

G2/M

40.50 ± 0.71

33.85 ± 1.20*

30.20 ± 0.28*

24.95 ± 0.07**

A549

G0/G1

65.82 ± 2.62

63.48 ± 4.47

66.62 ± 3.59

61.54 ± 1.14

S

14.10 ± 3.29

13.61 ± 2.64

11.55 ± 2.67

14.90 ± 0.36

G2/M

21.31 ± 0.83

24.56 ± 2.21*

23.40 ± 1.41*

25.18 ± 0.73*

DU145

G0/G1

56.24 ± 7.90

46.12 ±15.97

25.99 ± 7.43**

16.76 ± 1.61**

S

12.19 ± 3.79

16.36 ± 3.25

8.02 ± 2.14

8.57 ± 1.70

G2/M

29.89 ± 3.99

31.26 ± 5.85

56.97 ± 6.24**

55.93 ± 5.53**

HepG2

G0/G1

59.68 ± 0.09

47.17 ± 4.18*

23.23 ± 0.59**

19.91 ± 5.82**

S

12.33 ± 0.86

10.68 ± 2.74

7.04 ± 0.52*

7.91 ± 2.71

G2/M

26.39 ± 0.41

36.63 ± 7.25*

57.84 ± 1.53**

59.49 ±7.52**

Hela

G0/G1

62.42 ± 0.01

62.48 ± 0.08

63.49 ± 1.33

63.59 ± 2.26

S

10.35 ± 0.18

9.02 ± 0.59

8.19 ± 0.24

7.86 ± 0.33

G2/M

25.87 ± 0.27

26.36 ± 0.28

24.90 ± 0.32

26.19 ± 0.12

Hep-2

G0/G1

62.78 ± 4.35

69.50 ± 4.65

63.39 ± 0.07

61.83 ± 7.97

S

18.73 ± 2.57

12.72 ± 3.64

16.79 ± 0.73

17.77 ± 5.70

G2/M

20.66 ± 1.48

18.65 ± 1.92

20.31 ± 0.72

20.53 ± 2.57

  1. Results are expressed as the percentage of total cells. Data represent mean ± SD values of triplicate experiments. Tukey–Kramer Multiple Comparison test; *p < 0.05; **p < 0.01